Based on the results of the NALA study(Saura et al. 2020b), the FDA approved neratinib plus capecitabine for patients with advanced HER2-positive BC who have received more than 2 lines of anti-HER2 therapy, with systemic efficacy and intracranial activity. Here, ERBB2 is linked to breast cancer.